Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer
Max Mano and Yves Humblet*
Correspondence *Saint-Luc University Clinics, Medical Oncology, Avenue Hippocrate 10, 1200 Brussels, Belgium
Email humblet@onco.ucl.ac.be
More-effective systemic therapies are needed for colorectal cancer, and particularly for metastatic disease, for which median survival rates remain below 2 years. The addition of panitumumab to best supportive care has improved efficacy in patients with chemotherapy-refractory metastatic disease, and is associated with a favorable safety profile. The authors discuss the available data and ongoing investigations of this agent in the first-line and second-line settings.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.